2-(3-Fluorobenzoyl)-4-methylimidazole | 705947-14-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(3-Fluorobenzoyl)-4-methylimidazole
• 英文别名: (3-fluorophenyl)-(5-methyl-1H-imidazol-2-yl)methanone
• CAS: 705947-14-4
• 化学式: C₁₁H₉FN₂O
• 分子量: 204.204
• InChiKey: XVCYXWFGDRZTSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(3-Fluorobenzoyl)-4-methylimidazole 、 5-[(1-ethylpiperidin-4-yl)amino]-1,3-N-N-dihydro-2H-indol-2-one 以 乙醇 为溶剂， 生成 5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)-(5-methyl-1H-imidazol-2-yl)methylidene]-1H-indol-2-one
  参考文献：
  名称：

  The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors

  摘要：

  Variously substituted indolin-2-ones were synthesized and evaluated for activity against KDR, Flt-1, FGFR-1 and PDGFR. Extension at the 5-position of the oxindole ring with ethyl piperidine (compound 7i) proved to be the most beneficial for attaining both biochemical and cellular potencies. Further optimization of 7i to balance biochemical and cellular potencies with favorable ADME/ PK properties led to the identification of 8h, a compound with a clean CYP profile, acceptable pharmacokinetic and toxicity profiles, and robust efficacy in multiple xenograft tumor models. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.029
• 作为产物：
  描述：

  在 盐酸 、 水 、 ammonium hydroxide 作用下， 以 丙酮 为溶剂， 反应 0.5h， 生成 2-(3-Fluorobenzoyl)-4-methylimidazole
  参考文献：
  名称：

  The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors

  摘要：

  Variously substituted indolin-2-ones were synthesized and evaluated for activity against KDR, Flt-1, FGFR-1 and PDGFR. Extension at the 5-position of the oxindole ring with ethyl piperidine (compound 7i) proved to be the most beneficial for attaining both biochemical and cellular potencies. Further optimization of 7i to balance biochemical and cellular potencies with favorable ADME/ PK properties led to the identification of 8h, a compound with a clean CYP profile, acceptable pharmacokinetic and toxicity profiles, and robust efficacy in multiple xenograft tumor models. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.029

文献信息

• Kinase modulators
  申请人：Xu Wei

  公开号：US20060122171A1

  公开（公告）日：2006-06-08

  The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides oxindole derivatives which inhibit, regulate and/or modulate kinase receptor, particularly VEGF receptor 2 (Flk-1/KDR), FGFR1, and PDGFR (alpha and beta), signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.

  本发明提供了用于调节蛋白激酶酶活性以调节细胞活动（如增殖、分化、程序性细胞死亡、迁移和化学侵袭）的化合物。更具体地说，本发明提供了氧化吲哚衍生物，其抑制、调节和/或调节激酶受体，特别是VEGF受体2（Flk-1/KDR）、FGFR1和PDGFR（α和β）信号转导通路，与上述细胞活动变化相关的组合物，以及使用它们治疗激酶依赖性疾病和病状的方法。
• Substituted 3-(diarylmethylene)indolin-2-ones and methods of their use
  申请人：Symphony Evolution, Inc.

  公开号：US07626031B2

  公开（公告）日：2009-12-01

  The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides oxindole derivatives which inhibit, regulate and/or modulate kinase receptor, particularly VEGF receptor 2 (Flk-1/KDR), FGFR1, and PDGFR (alpha and beta), signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.

  本发明提供了用于调节蛋白激酶酶活性以调节细胞活动，如增殖、分化、程序性细胞死亡、迁移和化学入侵的化合物。更具体地，本发明提供了氧化吲哚衍生物，其抑制、调节和/或调节激酶受体，特别是VEGF受体2(Flk-1/KDR)，FGFR1和PDGFR(α和β)的信号转导通路，涉及上述细胞活动的变化，以及包含这些化合物的组合物和使用它们治疗激酶依赖性疾病和状况的方法。
• KINASE MODULATORS
  申请人：Exelixis, Inc.

  公开号：EP1581309A2

  公开（公告）日：2005-10-05
• EP1581309A4
  申请人：——

  公开号：EP1581309A4

  公开（公告）日：2009-07-29
• US7626031B2
  申请人：——

  公开号：US7626031B2

  公开（公告）日：2009-12-01